- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Investors once OK with waiting patiently for a Gilead rebound are growing frustrated, even angry, at the company's lack of progress.
GlaxoSmithKline (GSK) is working on a two-pill HIV regimen that could potentially change the standard of HIV treatment and push it ahead of rival pharmaceutical companies.
London based investment manager warns of further falls in U.K dividends.
Which stocks will be most favored by the corporate-bond purchases?